Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

This study is testing a new targeted drug called TYRA-200 in patients with advanced cholangiocarcinoma (bile duct cancer) that has a specific genetic change called an FGFR2 gene alteration. TYRA-200 is designed to block the abnormal FGFR2 protein that drives tumor growth. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced cholangiocarcinoma (bile duct cancer) confirmed by biopsy - Your tumor has an FGFR2 gene mutation, fusion, or amplification detected by a gene panel test - Your overall health and ability to function meets the required performance criteria - You have previously tried standard treatments or are not a candidate for them **You may NOT be eligible if...** - Your tumor does not have an FGFR2 gene alteration - You have not yet tried available standard therapies and are still eligible for them - Your general health or organ function does not meet the required thresholds - You have conditions that make FGFR-targeted therapy unsafe Talk to your doctor to see if this trial is right for you.